Serina Therapeutics, Inc.
601 Genome Way
Suite 2001
Huntsville, Alabama 35806
(256) 327-9630
July 5, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attention: Tim Buchmiller and Lauren Hamill
| Re: | Serina Therapeutics, Inc. |
| Registration Statement on Form S-1 | |
| File No. 333-279121 |
Ladies and Gentlemen;
In accordance with Rule 461 under the Securities Act of 1933, as amended, Serina Therapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Tuesday, July 9, 2024, or as soon thereafter as is practicable.
Please contact Stephen Hinton of Bradley Arant Boult Cummings LLP, the Company’s legal counsel, at (205) 521-8406, if you have any questions or concerns regarding this matter. Thank you in advance for your assistance.
| Sincerely, | ||
| SERINA THERAPEUTICS, INC. | ||
| By: | /s/ Andrea Park | |
| Name: | Andrea Park | |
| Title: | Interim Chief Financial Officer and Chief Accounting Officer | |
cc: Stephen Hinton, Bradley Arant Boult Cummings LLP